225 related articles for article (PubMed ID: 14695825)
21. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453
[TBL] [Abstract][Full Text] [Related]
22. Generation of an affinity matrix useful in the purification of natural inhibitors of plasmepsin II, an antimalarial-drug target.
Ramírez AR; Guerra Y; Otero A; García B; Berry C; Mendiola J; Hernández-Zanui A; Chávez Mde L
Biotechnol Appl Biochem; 2009 Feb; 52(Pt 2):149-57. PubMed ID: 18471091
[TBL] [Abstract][Full Text] [Related]
23. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors.
Ahmed W; Rani M; Khan IA; Iqbal A; Khan KM; Haleem MA; Azim MK
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):673-8. PubMed ID: 20063996
[TBL] [Abstract][Full Text] [Related]
24. A heterogeneous enzymatic assay for quantification of Plasmepsin II activity and the evaluation of its inhibitors.
Salas E; Ramírez A; Otero-Bilbao A; Vázquez R; Reyes O; Mendiola J; Duarte CA; Otero-González A; Gutiérrez OA; Chávez MA
J Pharm Biomed Anal; 2004 Mar; 34(4):833-40. PubMed ID: 15019062
[TBL] [Abstract][Full Text] [Related]
25. Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II.
Kiso A; Hidaka K; Kimura T; Hayashi Y; Nezami A; Freire E; Kiso Y
J Pept Sci; 2004 Nov; 10(11):641-7. PubMed ID: 15568678
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II.
Johansson PO; Lindberg J; Blackman MJ; Kvarnström I; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
J Med Chem; 2005 Jun; 48(13):4400-9. PubMed ID: 15974592
[TBL] [Abstract][Full Text] [Related]
27. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
[TBL] [Abstract][Full Text] [Related]
28. Plasmepsins as potential targets for new antimalarial therapy.
Ersmark K; Samuelsson B; Hallberg A
Med Res Rev; 2006 Sep; 26(5):626-66. PubMed ID: 16838300
[TBL] [Abstract][Full Text] [Related]
29. Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids.
Degliesposti G; Kasam V; Da Costa A; Kang HK; Kim N; Kim DW; Breton V; Kim D; Rastelli G
ChemMedChem; 2009 Jul; 4(7):1164-73. PubMed ID: 19437467
[TBL] [Abstract][Full Text] [Related]
30. Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
Azim MK; Ahmed W; Khan IA; Rao NA; Khan KM
Bioorg Med Chem Lett; 2008 May; 18(9):3011-5. PubMed ID: 18417344
[TBL] [Abstract][Full Text] [Related]
31. Active-site specificity of digestive aspartic peptidases from the four species of Plasmodium that infect humans using chromogenic combinatorial peptide libraries.
Beyer BB; Johnson JV; Chung AY; Li T; Madabushi A; Agbandje-McKenna M; McKenna R; Dame JB; Dunn BM
Biochemistry; 2005 Feb; 44(6):1768-79. PubMed ID: 15697202
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations.
Ersmark K; Nervall M; Hamelink E; Janka LK; Clemente JC; Dunn BM; Blackman MJ; Samuelsson B; Aqvist J; Hallberg A
J Med Chem; 2005 Sep; 48(19):6090-106. PubMed ID: 16162010
[TBL] [Abstract][Full Text] [Related]
33. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target.
Nezami A; Luque I; Kimura T; Kiso Y; Freire E
Biochemistry; 2002 Feb; 41(7):2273-80. PubMed ID: 11841219
[TBL] [Abstract][Full Text] [Related]
34. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum.
Silva AM; Lee AY; Gulnik SV; Maier P; Collins J; Bhat TN; Collins PJ; Cachau RE; Luker KE; Gluzman IY; Francis SE; Oksman A; Goldberg DE; Erickson JW
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10034-9. PubMed ID: 8816746
[TBL] [Abstract][Full Text] [Related]
35. New potent C2-symmetric malaria plasmepsin I and II inhibitors.
Oscarsson K; Oscarson S; Vrang L; Hamelink E; Hallberg A; Samuelsson B
Bioorg Med Chem; 2003 Apr; 11(7):1235-46. PubMed ID: 12628651
[TBL] [Abstract][Full Text] [Related]
36. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
[No Abstract] [Full Text] [Related]
37. Pepsinogen-like activation intermediate of plasmepsin II revealed by molecular dynamics analysis.
Friedman R; Caflisch A
Proteins; 2008 Dec; 73(4):814-27. PubMed ID: 18498105
[TBL] [Abstract][Full Text] [Related]
38. Catalysis and linear free energy relationships in aspartic proteases.
Bjelic S; Aqvist J
Biochemistry; 2006 Jun; 45(25):7709-23. PubMed ID: 16784222
[TBL] [Abstract][Full Text] [Related]
39. Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D.
Zogota R; Kinena L; Withers-Martinez C; Blackman MJ; Bobrovs R; Pantelejevs T; Kanepe-Lapsa I; Ozola V; Jaudzems K; Suna E; Jirgensons A
Eur J Med Chem; 2019 Feb; 163():344-352. PubMed ID: 30529637
[TBL] [Abstract][Full Text] [Related]
40. Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs'.
Romeo S; Dell'Agli M; Parapini S; Rizzi L; Galli G; Mondani M; Sparatore A; Taramelli D; Bosisio E
Bioorg Med Chem Lett; 2004 Jun; 14(11):2931-4. PubMed ID: 15125962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]